Recombinant Parvovirus-like Particles As an Antigen Carrier: a Novel Nonreplicative Exogenous Antigen to Elicit Protective Antiviral Cytotoxic T Cells

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1997 Jul 8

PMID 9207121

Citations 48

Authors

C Sedlik

M Saron

J Sarraseca

I Casal

C Leclerc

Affiliations

Soon will be listed here.

Abstract

To develop a strategy that promotes efficient antiviral immunity, hybrid virus-like particles (VLP) were prepared by self-assembly of the modified porcine parvovirus VP2 capsid protein carrying a CD8(+) T cell epitope from the lymphocytic choriomeningitis virus nucleoprotein. Immunization of mice with these hybrid pseudoparticles, without adjuvant, induced strong cytotoxic T lymphocyte (CTL) responses against both peptide-coated- or virus-infected-target cells. This CD8(+) class I-restricted cytotoxic activity persisted in vivo for at least 9 months. Furthermore, the hybrid parvovirus-like particles were able to induce a complete protection of mice against a lethal lymphocytic choriomeningitis virus infection. To our knowledge, this study represents the first demonstration that hybrid nonreplicative VLP carrying a single viral CTL epitope can induce protection against a viral lethal challenge, in the absence of any adjuvant. These recombinant particles containing a single type of protein are easily produced by the baculovirus expression system and, therefore, represent a promising and safe strategy to induce strong CTL responses for the elimination of virus-infected cells.

Citing Articles

Stability and integrity of self-assembled bovine parvovirus virus‑like particles (BPV‑VLPs) of VP2 and combination of VP1VP2 assisted by baculovirus-insect cell expression: a potential logistical platform for vaccine deployment.

Wubshet A, Li G, Li Q, Dai J, Ding Y, Zhou L Virol J. 2024; 21(1):87.

PMID: 38641833 PMC: 11027344. DOI: 10.1186/s12985-024-02322-0.

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice.

Chen C, Saubi N, Kilpelainen A, Joseph-Munne J Vaccines (Basel). 2023; 11(1).

PMID: 36679860 PMC: 9861546. DOI: 10.3390/vaccines11010015.

Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.

Coughlan L, Kremer E, Shayakhmetov D Mol Ther. 2022; 30(5):1822-1849.

PMID: 35092844 PMC: 8801892. DOI: 10.1016/j.ymthe.2022.01.034.

A Novel Recombinant Virus-Like Particles Displaying B and T Cell Epitopes of Japanese Encephalitis Virus Offers Protective Immunity in Mice and Guinea Pigs.

Anwar M, Jiang C, Di D, Zhang J, Guo S, Wang X Vaccines (Basel). 2021; 9(9).

PMID: 34579217 PMC: 8473392. DOI: 10.3390/vaccines9090980.

Investigation of Kluyveromyces marxianus as a novel host for large-scale production of porcine parvovirus virus-like particles.

Yang D, Chen L, Duan J, Yu Y, Zhou J, Lu H Microb Cell Fact. 2021; 20(1):24.

PMID: 33494762 PMC: 7836160. DOI: 10.1186/s12934-021-01514-5.

References

Castrucci M, Hou S, Doherty P, Kawaoka Y . Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. J Virol. 1994; 68(6):3486-90. PMC: 236851. DOI: 10.1128/JVI.68.6.3486-3490.1994. View

Schirmbeck R, Melber K, Mertens T, Reimann J . Selective stimulation of murine cytotoxic T cell and antibody responses by particulate or monomeric hepatitis B virus surface (S) antigen. Eur J Immunol. 1994; 24(5):1088-96. DOI: 10.1002/eji.1830240512. View

Ke Y, Li Y, Kapp J . Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur J Immunol. 1995; 25(2):549-53. DOI: 10.1002/eji.1830250237. View

Harding C, Pfeifer J . Antigen expressed by Salmonella typhimurium is processed for class I major histocompatibility complex presentation by macrophages but not infected epithelial cells. Immunology. 1994; 83(4):670-4. PMC: 1415070. View

Altmeyer R, Girard M, van der Werf S, Mimic V, Seigneur L, Saron M . Attenuated Mengo virus: a new vector for live recombinant vaccines. J Virol. 1995; 69(5):3193-6. PMC: 189023. DOI: 10.1128/JVI.69.5.3193-3196.1995. View

Gengoux C, Leclerc C . In vivo induction of CD4+ T cell responses by antigens covalently linked to synthetic microspheres does not require adjuvant. Int Immunol. 1995; 7(1):45-53. DOI: 10.1093/intimm/7.1.45. View

Irvine K, McCabe B, Rosenberg S, Restifo N . Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol. 1995; 154(9):4651-7. PMC: 1976247. View

Pialoux G, Excler J, Riviere Y, Feuillie V, Coulaud P, Gluckman J . A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses. 1995; 11(3):373-81. DOI: 10.1089/aid.1995.11.373. View

Winter N, Lagranderie M, Gangloff S, Leclerc C, Gheorghiu M, Gicquel B . Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine. 1995; 13(5):471-8. DOI: 10.1016/0264-410x(94)00001-4. View

10.

Sedlik C, Sarraseca J, Rueda P, Leclerc C, Casal I . Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles. J Gen Virol. 1995; 76 ( Pt 9):2361-8. DOI: 10.1099/0022-1317-76-9-2361. View

11.

Nair S, Buiting A, Rouse R, van Rooijen N, Huang L, Rouse B . Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. Int Immunol. 1995; 7(4):679-88. DOI: 10.1093/intimm/7.4.679. View

12.

Goossens P, Milon G, Cossart P, Saron M . Attenuated Listeria monocytogenes as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int Immunol. 1995; 7(5):797-805. DOI: 10.1093/intimm/7.5.797. View

13.

Schirmbeck R, Bohm W, Melber K, Reimann J . Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J Immunol. 1995; 155(10):4676-84. View

14.

Weber J, CALLOW D, Adams S, Patou G, Hodgkin K, Martin S . Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine. 1995; 13(9):831-4. DOI: 10.1016/0264-410x(94)00061-q. View

15.

Norbury C, Hewlett L, Prescott A, Shastri N, Watts C . Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity. 1995; 3(6):783-91. DOI: 10.1016/1074-7613(95)90067-5. View

16.

Slifka M, Shen H, Matloubian M, Jensen E, Miller J, Ahmed R . Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes. J Virol. 1996; 70(5):2902-10. PMC: 190148. DOI: 10.1128/JVI.70.5.2902-2910.1996. View

17.

Fayolle C, Sebo P, Ladant D, Ullmann A, Leclerc C . In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol. 1996; 156(12):4697-706. View

18.

Ulmer J, Sadoff J, Liu M . DNA vaccines. Curr Opin Immunol. 1996; 8(4):531-6. DOI: 10.1016/s0952-7915(96)80042-2. View

19.

Harris S, Woodrow S, Gearing A, Adams S, Kingsman A, Layton G . The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice. Vaccine. 1996; 14(10):971-6. DOI: 10.1016/0264-410x(96)00010-2. View

20.

Lehmann-Grube F . LYMPHOCYTIC CHORIOMENINGITIS IN THE MOUSE. I. GROWTH IN THE BRAIN. Arch Gesamte Virusforsch. 1964; 14:344-50. DOI: 10.1007/BF01555827. View